Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.
2021
Targeted pharmacologic activation of antigen-specific (AgS) T cells may bypass limitations inherent in current T cell-based cancer therapies. We describe two immunotherapeutics platforms for selective delivery of costimulatory ligands and peptide-HLA (pHLA) to AgS T cells. We engineered and deployed on these platforms an affinity-attenuated variant of interleukin-2, which selectively expands oligoclonal and polyfunctional AgS T cells in vitro and synergizes with CD80 signals for superior proliferation versus peptide stimulation.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
32
References
0
Citations
NaN
KQI